William Oelke, in Hudson, WI - Behavior Analyst

William Oelke, is a Behavior Analyst based in Hudson, Wisconsin. William Oelke is licensed to practice in Wisconsin (license number 140-140) and his current practice location is 901 Dominion Dr Ste A, Hudson, Wisconsin. He can be reached at his office (for appointments etc.) via phone at (612) 327-6620.

NPI number for William Oelke is 1124481973 and his current mailing address is 901 Dominion Dr Ste A, Hudson, Wisconsin. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1124481973.

Contact Information

	William Oelke,
	901 Dominion Dr Ste A, Hudson, WI 54016-9333
	(612) 327-6620
	(952) 938-8838

Healthcare Provider's Profile

Full Name	William Oelke
Gender	Male
Speciality	Behavior Analyst
Location	901 Dominion Dr Ste A, Hudson, Wisconsin
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1124481973
Provider Enumeration Date: 03/30/2016
Last Update Date: 01/15/2020

Medical Identifiers

Medical identifiers for William Oelke such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1124481973	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
101YM0800X	Counselor - Mental Health	1385 (Minnesota)	Secondary
103K00000X	Behavior Analyst	140-140 (Wisconsin)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. William Oelke is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
William Oelke, 901 Dominion Dr Ste A, Hudson, WI 54016-9333 Ph: (715) 808-8555	William Oelke, 901 Dominion Dr Ste A, Hudson, WI 54016-9333 Ph: (612) 327-6620

News Archive

Genentech, Xenon partner to discover and develop novel pain relieving medicines

Xenon today announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.

OGT produces free-to-download whitepaper on targeted resequencing strategies

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a new, free-to-download whitepaper titled ‘When to use targeted resequencing — Choosing the right NGS method.'

Study: Neural reserve, neural compensation activated in highly educated prodromal Alzheimer's patients

Highly educated individuals with mild cognitive impairment that later progressed to Alzheimer's disease cope better with the disease than individuals with a lower level of education in the same situation, according to research published in the June issue of The Journal of Nuclear Medicine.

Low levels of BPA exposure can affect prenatal brain development

Humans are exposed to a bath of chemicals every day. They are in the beds where we sleep, the cars that we drive and the kitchens we use to feed our families.

New drug to combat Gastrointestinal graft-vs.-host disease in stem-cell patients shows significant reduction in deaths

Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers.

William Oelke, - Counselor in Hudson, WI